# A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis

> **NCT07103369** · PHASE1 · COMPLETED · sponsor: **SinoMab BioScience Ltd** · enrollment: 64 (actual)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **DRUG:** SM17 for injection
- **OTHER:** SM17 placebo for injection

## Key facts

- **NCT ID:** NCT07103369
- **Lead sponsor:** SinoMab BioScience Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-21
- **Primary completion:** 2025-03-24
- **Final completion:** 2025-03-31
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07103369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07103369, "A Phase I Clinical Study to Evaluate SM17 in Chinese Healthy Subjects and Patients With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07103369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*